Medical education: Bridging science and clinical practice
As the pharmaceutical industry continues to accelerate innovation, one challenge remains constant: ensuring that groundbreaking therapies translate into meaningful improvements in patient care. Clinical evidence may generate awareness, but real-world adoption requires far more than data alone. It demands confidence, practical understanding, and the ability for healthcare professionals to apply new evidence within the realities of everyday clinical practice.
To explore this further, pharmaphorum spoke with Emily Harrison, founder and managing director of Nexus Healthcare Education [HE], to explore the critical role medical education plays in bridging the gap between scientific advancement and clinical implementation. From overcoming barriers to adoption and supporting behavioural change, to measuring long-term impact and improving patient outcomes – Harrison shares her perspective on how education can move beyond information delivery to become a true driver of transformation in healthcare.
Q. In pharma, success increasingly depends not just on awareness, but on real-world adoption. How does medical education bridge that gap?
Emily Harrison: Medical education plays a critical role in translating scientific evidence into practical clinical action. Awareness alone does not change patient outcomes. Clinicians need to understand not only the data, but also how to apply it within the realities of day-to-day practice, across different healthcare systems, patient populations, and resource settings.
The most effective education bridges the gap by focusing on implementation, not just information transfer. That means helping healthcare professionals understand where new evidence fits into existing pathways, how to identify the right patients, how to overcome practical barriers, and how to make confident treatment decisions in real-world scenarios.
We believe education should support clinicians throughout the full adoption journey, from awareness and understanding, through to competence, confidence and, ultimately, sustained changes in clinical practice and patient care.
Q. Why do so many promising therapies struggle to translate from clinical evidence into routine practice, even when the data is compelling?
Clinical evidence alone is rarely enough to change behaviour. Healthcare professionals are managing increasingly complex patient populations, growing administrative pressures, evolving guidelines, and significant time constraints. Even when the evidence is strong, translating it into routine care can be challenging.
There are often multiple barriers between evidence generation and implementation. These include uncertainty around patient selection, concerns regarding safety or monitoring, lack of familiarity with new mechanisms of action, limited multidisciplinary alignment, restricted access pathways, or simply clinical inertia within established treatment paradigms.
Importantly, clinicians also need to see how evidence applies to the patients sitting in front of them, not just those enrolled in clinical trials. Education that contextualises evidence through practical case-based learning, peer discussion, and real-world application is far more likely to support meaningful adoption.
Q. When a new treatment enters the market, what are the biggest barriers preventing healthcare professionals from changing established practice?
One of the biggest barriers is confidence. Clinicians may understand the evidence intellectually, but still feel uncertain about how to integrate a new therapy into clinical workflows, particularly in complex or high-risk patient populations.
Another major challenge is identifying where the treatment fits within an already crowded and evolving treatment landscape. Clinicians are constantly balancing guidelines, emerging data, institutional protocols, reimbursement restrictions, and patient preferences. Without clear practical guidance, adoption can understandably be slow.
There is also the challenge of time. Healthcare professionals are overwhelmed with information, and traditional educational models often do not reflect how clinicians learn or make decisions in modern practice. Education needs to be concise, relevant, accessible, and directly applicable to patient care if it is going to drive real change.
Q. How can education programmes help clinicians move from "I understand the evidence" to "I feel confident using this in my patients"?
Confidence comes from application. Education programmes are most effective when they move beyond passive learning and allow clinicians to actively engage with decision-making.
Case-based learning is particularly powerful because it mirrors real clinical practice. It helps clinicians explore patient selection, treatment sequencing, monitoring, adverse event management, multidisciplinary collaboration, and communication challenges in a practical way.
Peer-to-peer learning is also extremely important. Clinicians often gain confidence by hearing how other experts approach similar decisions, particularly when discussing nuanced or difficult cases.
At Nexus Healthcare Education, we focus heavily on creating education that supports behavioural change, not just knowledge acquisition. That means designing programmes that are interactive, clinically relevant, outcomes-focused, and longitudinal, allowing learners to build confidence over time, rather than through a single educational encounter.
Q. How should pharma companies measure the impact of education programmes?
Educational impact should be measured far beyond attendance numbers or satisfaction scores. Participation alone does not demonstrate whether education has changed clinical practice or improved patient care.
Pharma companies should increasingly focus on outcomes-based measurement frameworks that assess progression across multiple levels, including knowledge, competence, confidence, performance, and patient impact.
For instance, we use our proprietary GAUGE framework to track learner progression longitudinally across educational activities. This allows us to assess not only whether clinicians engaged with the education, but whether they retained knowledge, changed clinical decision-making, and applied learning within practice over time.
The goal of medical education should be measurable improvement in healthcare delivery and patient outcomes and the measurement strategy should reflect that ambition.
Q. Ultimately, what separates education programmes that simply inform from those that genuinely transform clinical practice?
Transformative education changes behaviour, not just awareness.
The programmes that genuinely drive change are those that are grounded in clearly identified clinical practice gaps, aligned with real-world barriers, and designed around how clinicians actually learn and implement evidence in practice.
They are also highly practical. Rather than simply presenting data, they focus on decision-making, implementation strategies, multidisciplinary collaboration, and patient-centred care.
Importantly, transformative programmes are not one-off events. Changing practice takes time, reinforcement, and repeated engagement. Longitudinal education, supported by outcomes measurement and adaptive learning approaches, is far more likely to create sustainable impact.
The future of medical education is not simply delivering content, it is supporting clinicians through the full process of translating evidence into better patient care.
Q. Anything else to add?
Healthcare is evolving at an extraordinary pace, and the volume of emerging evidence continues to grow rapidly. The challenge is no longer access to information, it is helping clinicians interpret, prioritise, and apply that information meaningfully in practice.
Medical education therefore has a responsibility not only to educate, but also to simplify complexity, reduce implementation gaps, and ultimately support better outcomes for patients.
There is also a growing opportunity to use data, technology, and outcomes science to make education more personalised, adaptive, and measurable than ever before. We believe the future of medical education will increasingly focus on demonstrating real-world impact, supporting implementation science, and creating learning experiences that drive sustained clinical change, rather than short-term engagement alone.
About the interviewee
As managing director and founder of Nexus Healthcare Education, Emily Harrison aims to lead advancements in medical education. She has a background in healthcare education, which guides her approach to introducing innovative and accessible educational solutions for healthcare professionals worldwide.
